health
Preprint finds surrogate endpoints dominate US cancer-drug approvals
A medRxiv analysis of 354 FDA oncology approvals from 2014 through early 2025 found surrogate endpoints had become the dominant primary measure used for approval. The authors also reported different relationships between surrogate-endpoint benefits and overall survival for immunotherapy and non-immunotherapy approvals.